According to the findings of a post-hoc analysis from three phase 3 randomized trials, oral Rimegepant was beneficial for the acute management of migraine in both current Triptan users and those who had an inadequate response to 1 or > 2 triptans.  Researchers sought to evaluate the effectiveness of calcitonin gene-related peptide receptor antagonist in treating adult migraineurs on the basis of Triptan treatment experience.

According to their prior experience with triptans, the participants were divided into 4 groups: those who had an inadequate response (like lack of effectiveness and/or poor tolerability) to one Triptan, those who had an inadequate response to >2 triptans, those who were currently taking triptans, and those who had never taken a Triptan. Freedom from pain and freedom from the most annoying symptoms at two hours after dose were the co-primary effectiveness outcomes.

In the 3 trials (N = 3507; Rimegepant n = 1749, placebo n = 1758), 35.2% (n = 1235) participants had a history of inadequate response to 1 Triptan (n = 910 [25.9%]) or  >2 triptans (n = 325 [9.3%]), and 64.8% (n = 2272) had no history of inadequate response to triptans (current use = 595 [17.0%], naı¨ve = 1677 [47.8%]). Rimegepant was efficient on the co-primary endpoints in all subgroups, with the exception of the Triptan-naive group's independence from the most bothersome symptom.

In pairwise comparisons of people who had received Rimegepant, there were no differences in the co-primary outcomes. In adults having a history of inadequate response to one or >2 triptans as well as those who are currently taking triptans, Rimegepant was helpful to relieve migraine. The frequency of inadequate Triptan responses had no impact on the efficacy of the co-primary outcomes.